GlaxoSmithKline

GSK at #33 — now trading as GSK rather than GlaxoSmithKline in most contexts — with a 4.23% stock gain and sentiment of 0.20, steady as the pharma sector navigates post-COVID portfolio rebalancing. Culture at 40 and Business at 76 is the lowest Business score in the Health cohort, reflecting ongoing uncertainty about the Haleon spinoff and pipeline credibility. The rebrand to GSK was supposed to signal reinvention; the scores suggest it signaled contraction.